Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aligos Therapeutics (ALGS)
NASDAQ:ALGS
Holding ALGS?
Track your performance easily
ALGS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.76 - $30.00
Previous Close$9.48
Volume32.11K
Average Volume (3M)94.02K
Market Cap
$59.55M
Enterprise Value-$26.26M
Total Cash (Recent Filing)$94.54M
Total Debt (Recent Filing)$9.84M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Mar 06, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,196,103
10 Day Avg. Volume211,572
30 Day Avg. Volume94,017
Standard Deviation0.28
R-Squared0.13
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.45
Price to Sales (P/S)3.83
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-4.76
Enterprise Value/Gross Profit-4.24
Enterprise Value/Ebitda0.25
Forecast
1Y Price Target
$125.00Price Target Upside1194.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Aligos Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ALGS FAQ
What was Aligos Therapeutics’s price range in the past 12 months?
Aligos Therapeutics lowest stock price was $6.76 and its highest was $30.00 in the past 12 months.
What is Aligos Therapeutics’s market cap?
Currently, no data Available
When is Aligos Therapeutics’s upcoming earnings report date?
Aligos Therapeutics’s upcoming earnings report date is Mar 06, 2025 which is in 121 days.
How were Aligos Therapeutics’s earnings last quarter?
Currently, no data Available
Is Aligos Therapeutics overvalued?
According to Wall Street analysts Aligos Therapeutics’s price is currently Undervalued.
Does Aligos Therapeutics pay dividends?
Aligos Therapeutics does not currently pay dividends.
What is Aligos Therapeutics’s EPS estimate?
Aligos Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aligos Therapeutics have?
Aligos Therapeutics has 3,072,409 shares outstanding.
What happened to Aligos Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aligos Therapeutics?
Among the largest hedge funds holding Aligos Therapeutics’s share is Baker Bros Advisors LP. It holds Aligos Therapeutics’s shares valued at 727K.
---
Aligos Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$125.00 (1194.00% Upside)
$125.00 (1194.00% Upside)
Hedge Fund Trend
Decreased
By 13.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 8.5%
Last 30 Days ▲ 8.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.11%
12-Months-Change
Fundamentals
Return on Equity
-110.67%
Trailing 12-Months
Asset Growth
2.53%
Trailing 12-Months
Company Description
Aligos Therapeutics
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH).
---
ALGS Stock 12 Month Forecast
Average Price Target
$125.00
▲(1194.00% Upside)
Technical Analysis
Best Analysts Covering ALGS
1 Year
1 Year Success Rate
0/16 ratings generated profit
1 Year Average Return
-53.63%
reiterated a buy rating last month
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -53.63% per trade.
---